GOLETA, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN) today announced the pricing of 2,100,775 shares of its common stock at $21.50 per share in a secondary offering. All of the shares will be sold by existing stockholders. In addition, the underwriters have a 30-day option to purchase up to 315,116 additional shares of common stock from the selling stockholders.
Inogen, Inc. will not receive any proceeds from the sale of the shares in this offering. The primary purposes of the offering are to facilitate an orderly distribution of shares and to increase the company's public float.
The offering is expected to close on or about November 4, 2014, subject to satisfaction of customary closing conditions. J.P. Morgan is acting as sole book-running manager for the offering, William Blair is acting as lead manager, and Leerink Partners and Needham & Company are acting as co-managers.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained (when available) from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected closing of the public offering. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including the risks and uncertainties associated with market conditions and the completion of the public offering on the anticipated terms or at all. Information on these and additional risks, uncertainties, and other information affecting Inogen's business and operating results are contained in Inogen's Form S-1 filed with the Securities and Exchange Commission on October 14, 2014, as amended from time to time, Inogen's Annual Report on Form 10-K for the year ended December 31, 2013, and in Inogen's subsequent reports on Form 10-Q and Form 8-K. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
CONTACT: Investor Relations contact: 805-562-0500 ext: 7